Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the Stifel Healthcare Conference. The company's management will engage in a fireside chat on November 19th at 3:35 pm ET in New York City, along with one-on-one investor meetings.
The fireside chat will be available via webcast, accessible through both a direct link and the Events and Presentations section of Fulcrum's website. A replay will remain available for at least 30 days after the presentation.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel Healthcare Conference in New York City on November 19th at 3:35 pm ET. Management will also participate in one-on-one investor meetings.
The webcast of the fireside chat will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the Stifel Healthcare Conference 2024?
How can investors access Fulcrum Therapeutics' (FULC) Stifel Conference presentation?
How long will the replay of Fulcrum Therapeutics' (FULC) Stifel presentation be available?
What type of presentation will Fulcrum Therapeutics (FULC) give at the Stifel Healthcare Conference?
